Abstract
Incorporation of novel agents has resulted in an improved response rate and reduced side effects in multiple myeloma. This has prompted combining novel agents in induction chemotherapy in patients with newly diagnosed multiple myeloma. Our patients received 2 cycles of vincristine, adriamycin, dexamethasone (VAD) and then 2 cycles of bortezomib, thalidomide, dexamethasone (VTD) chemotherapy as an induction treatment. Subsequently, autologous stem cell transplantation was performed, and bortezomib was administered as a consolidation therapy. Seventy-one patients were enrolled, and 65 were evaluable for response. After 2 cycles of VAD, the overall response rate was 69%. After VTD, the response rate improved to 97% with a complete response (CR) and near CR rate of 27%. Importantly, patients with cytogenetics, having poor prognostic features, all responded after VTD. Autologous stem cells were successfully collected in all 58 patients with a median CD34+ cell count of 7.12 × 106/kg (range, 1.94–44.7 × 106/kg), except in 1 patient (2%). After ASCT, 36 patients completed bortezomib maintenance with a combined CR and near CR rate approaching 75%. Median time to response was rapid (1.6 months). With a median follow-up duration of 52.7 months, the median TTP was 29.4 months and median OS was not reached. Toxicities proved manageable. In conclusion, sequential VAD and VTD induction therapy in patients with newly diagnosed multiple myeloma was active with manageable toxicity and excellent stem cell yields. The incorporation of bortezomib as a consolidation therapy improved the clinical outcome with the expense of rather frequent development of peripheral neuropathy.
Similar content being viewed by others
References
Kyle RA, Rajkumar SV (2004) Multiple myeloma. N Engl J Med 351(18):1860–1873
Rajkumar SV, Kyle RA (2005) Multiple myeloma: diagnosis and treatment. Mayo Clin Proc 80(10):1371–1382
Savage L (2007) Unreported VA data may affect SEER research, cancer surveillance, and statistics gathering. J Natl Cancer Inst 99(23):1744–1745, 1752
Attal M et al (1996) A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. Intergroupe Francais du Myelome. N Engl J Med 335(2):91–97
Child JA et al (2003) High-dose chemotherapy with hematopoietic stem-cell rescue for multiple myeloma. N Engl J Med 348(19):1875–1883
Palumbo A et al (2004) Intermediate-dose melphalan improves survival of myeloma patients aged 50 to 70: results of a randomized controlled trial. Blood 104(10):3052–3057
Alexanian R, Barlogie B, Tucker S (1990) VAD-based regimens as primary treatment for multiple myeloma. Am J Hematol 33(2):86–89
Sirohi B, Powles R (2004) Multiple myeloma. Lancet 363(9412):875–887
Mileshkin L et al (2003) Multicenter phase 2 trial of thalidomide in relapsed/refractory multiple myeloma: adverse prognostic impact of advanced age. Blood 102(1):69–77
Dimopoulos MA et al (2001) Thalidomide and dexamethasone combination for refractory multiple myeloma. Ann Oncol 12(7):991–995
Dingli D et al (2005) Combination therapy with thalidomide and dexamethasone in patients with newly diagnosed multiple myeloma not undergoing upfront autologous stem cell transplantation: a phase II trial. Haematologica 90(12):1650–1654
Rajkumar SV et al (2006) Phase III clinical trial of thalidomide plus dexamethasone compared with dexamethasone alone in newly diagnosed multiple myeloma: a clinical trial coordinated by the Eastern Cooperative Oncology Group. J Clin Oncol 24(3):431–436
Adams J et al (1999) Proteasome inhibitors: a novel class of potent and effective antitumor agents. Cancer Res 59(11):2615–2622
Richardson PG et al (2003) A phase 2 study of bortezomib in relapsed, refractory myeloma. N Engl J Med 348(26):2609–2617
Richardson PG et al (2006) Extended follow-up of a phase II trial in relapsed, refractory multiple myeloma: final time-to-event results from the SUMMIT trial. Cancer 106(6):1316–1319
Jagannath S et al (2004) A phase 2 study of two doses of bortezomib in relapsed or refractory myeloma. Br J Haematol 127(2):165–172
Jagannath S et al (2006) Bortezomib in combination with dexamethasone for the treatment of patients with relapsed and/or refractory multiple myeloma with less than optimal response to bortezomib alone. Haematologica 91(7):929–934
Richardson PG et al (2005) Bortezomib or high-dose dexamethasone for relapsed multiple myeloma. N Engl J Med 352(24):2487–2498
Richardson PG et al (2007) Extended follow-up of a phase 3 trial in relapsed multiple myeloma: final time-to-event results of the APEX trial. Blood 110(10):3557–3560
Jagannath S et al (2005) Bortezomib therapy alone and in combination with dexamethasone for previously untreated symptomatic multiple myeloma. Br J Haematol 129(6):776–783
Pineda-Roman M et al (2008) VTD combination therapy with bortezomib-thalidomide-dexamethasone is highly effective in advanced and refractory multiple myeloma. Leukemia 22(7):1419–1427
Cavo M et al (2010) Bortezomib with thalidomide plus dexamethasone compared with thalidomide plus dexamethasone as induction therapy before, and consolidation therapy after, double autologous stem-cell transplantation in newly diagnosed multiple myeloma: a randomised phase 3 study. Lancet 376(9758):2075–2085
Cavo M et al (2011) International Myeloma Working Group consensus approach to the treatment of multiple myeloma patients who are candidates for autologous stem cell transplantation. Blood 117(23):6063–6073
Uy GL et al (2009) Bortezomib administered pre-auto-SCT and as maintenance therapy post transplant for multiple myeloma: a single institution phase II study. Bone Marrow Transplant 43(10):793–800
Durie BG et al (2006) International uniform response criteria for multiple myeloma. Leukemia 20(9):1467–1473
Trotti A et al (2003) CTCAE v3.0: development of a comprehensive grading system for the adverse effects of cancer treatment. Semin Radiat Oncol 13(3):176–181
Kim JS et al (2009) Complete remission status before autologous stem cell transplantation is an important prognostic factor in patients with multiple myeloma undergoing upfront single autologous transplantation. Biol Blood Marrow Transplant 15(4):463–470
Barlogie B et al (2008) Complete remission sustained 3 years from treatment initiation is a powerful surrogate for extended survival in multiple myeloma. Cancer 113(2):355–359
Raje N et al (1997) A comparison of vincristine and doxorubicin infusional chemotherapy with methylprednisolone (VAMP) with the addition of weekly cyclophosphamide (C-VAMP) as induction treatment followed by autografting in previously untreated myeloma. Br J Haematol 97(1):153–160
Moreau P et al (2002) Comparison of 200 mg/m(2) melphalan and 8 Gy total body irradiation plus 140 mg/m(2) melphalan as conditioning regimens for peripheral blood stem cell transplantation in patients with newly diagnosed multiple myeloma: final analysis of the Intergroupe Francophone du Myelome 9502 randomized trial. Blood 99(3):731–735
Cavo M et al (2005) Superiority of thalidomide and dexamethasone over vincristine-doxorubicindexamethasone (VAD) as primary therapy in preparation for autologous transplantation for multiple myeloma. Blood 106(1):35–39
Hussein MA et al (2009) Phase II study of thalidomide plus dexamethasone induction followed by tandem melphalan-based autotransplantation and thalidomide-plus-prednisone maintenance for untreated multiple myeloma: a southwest oncology group trial (S0204). J Clin Oncol 27(21):3510–3517
Harousseau JL et al (2006) Bortezomib plus dexamethasone as induction treatment prior to autologous stem cell transplantation in patients with newly diagnosed multiple myeloma: results of an IFM phase II study. Haematologica 91(11):1498–1505
Harousseau JL et al (2010) Bortezomib plus dexamethasone is superior to vincristine plus doxorubicin plus dexamethasone as induction treatment prior to autologous stem-cell transplantation in newly diagnosed multiple myeloma: results of the IFM 2005–01 phase III trial. J Clin Oncol 28(30):4621–4629
Avet-Loiseau H et al (2007) Genetic abnormalities and survival in multiple myeloma: the experience of the Intergroupe Francophone du Myelome. Blood 109(8):3489–3495
Terpos E, Eleutherakis-Papaiakovou V, Dimopoulos MA (2006) Clinical implications of chromosomal abnormalities in multiple myeloma. Leuk Lymphoma 47(5):803–814
Fonseca R et al (2004) Genetics and cytogenetics of multiple myeloma: a workshop report. Cancer Res 64(4):1546–1558
Fonseca R et al (2002) Myeloma and the t(11;14)(q13;q32); evidence for a biologically defined unique subset of patients. Blood 99(10):3735–3741
Richardson PG et al (2005) Clinical factors predictive of outcome with bortezomib in patients with relapsed, refractory multiple myeloma. Blood 106(9):2977–2981
Jagannath S et al (2007) Bortezomib appears to overcome the poor prognosis conferred by chromosome 13 deletion in phase 2 and 3 trials. Leukemia 21(1):151–157
Mellqvist UHM et al (2009) Improved response rate with bortezomib consolidation after high dose melphalan: first results of a Nordic Myeloma Study Group randomized phase III trial. Blood 114(22) (Abstract 530)
Palumbo A et al (2008) Prevention of thalidomide- and lenalidomide-associated thrombosis in myeloma. Leukemia 22(2):414–423
Koh Y et al (2010) Low incidence of clinically apparent thromboembolism in Korean patients with multiple myeloma treated with thalidomide. Ann Hematol 89(2):201–206
Abdelkefi A et al (2005) First-line thalidomide-dexamethasone therapy in preparation for autologous stem cell transplantation in young patients (<61 years) with symptomatic multiple myeloma. Bone Marrow Transplant 36(3):193–198
Attal M et al (2006) Maintenance therapy with thalidomide improves survival in patients with multiple myeloma. Blood 108(10):3289–3294
Schiller G et al (2008) Phase I/II trial of bortezomib maintenance following autologous peripheral blood progenitor cell transplantation as treatment for intermediate-and advanced-stage multiple myeloma. Biol Blood Marrow Transplant 14, Absract 176
Sonneveld P et al (2010) HOVON-65/GMMG-HD4 randomized phase III trial comparing bortezomib, doxorubicin, dexamethasone (PAD) vs. VAD followed by high-dose melphalan (HDM) and maintenance with bortezomib or thalidomide in patients with newly diagnosed multiple myeloma (MM). Blood 116, Abstract 40
Benevolo G et al (2011) The efficacy and safety of bortezomib and dexamethasone as a maintenance therapy in patients with advanced multiple myeloma who are responsive to salvage bortezomib-containing regimens. Cancer 119:1884–1890
Palumbo A et al (2010) Bortezomib as induction before autologous transplantation, followed by lenalidomide as consolidation-maintenance in untreated multiple myeloma patients. J Clin Oncol 28(5):800–807
Acknowledgments
The authors would like to thank Sun Jong Lee for her efforts in data collection, Yun Jeong Kim for her administrative assistance, and KMMWP. This work was supported by a grant of (1) the Korea Health 21 R&D Project, Ministry for Health, Welfare and Family Affairs, R.O.K. (A084783) and (2) the Korea Health 21 R&D project, Ministry for Health, Welfare and Family Affairs, R.O.K. (A030001) and in part, by Janssen Korea.
Financial disclosure statement
The authors have nothing to disclose.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Kim, H.J., Yoon, SS., Lee, D.S. et al. Sequential vincristine, adriamycin, dexamethasone (VAD) followed by bortezomib, thalidomide, dexamethasone (VTD) as induction, followed by high-dose therapy with autologous stem cell transplant and consolidation therapy with bortezomib for newly diagnosed multiple myeloma: results of a phase II trial. Ann Hematol 91, 249–256 (2012). https://doi.org/10.1007/s00277-011-1298-9
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00277-011-1298-9